Catenacci DV et al. MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress. ESMO 2021;Abstract 1434TiP.
Chung HC et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol 2021;17(5):491-501. Abstract
Cohen DJ et al. A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015. ASCO Gastrointestinal Cancers Symposium 2022;Abstract TPS369.
Cowzer D, Janjigian Y. Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer 2022;128(10):1894-9. Abstract
Janjigian YY et al. Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. ASCO Gastrointestinal Cancers Symposium 2022;Abstract 295.
Janjigian YY et al. Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot. Cancer Cell 2021;39(6):738-42. Abstract
Janjigian YY et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27-40. Abstract
Janjigian YY et al. Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. ESMO 2021;Abstract LBA7.
Janjigian YY et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600(7890):727-30. Abstract
Kundra R et al. OncoTree: A cancer classification system for precision oncology. JCO Clin Cancer Inform 2021;5:221-30. Abstract
Moy RH et al. A nutritional management algorithm in older patients with locally advanced esophageal cancer. J Geriatr Oncol 2022;13(1):100-3. Abstract
Nobel TB et al. Oligometastases after curative esophagectomy are not one size fits all. Ann Thorac Surg 2021;112(6):1775-81. Abstract
Shitara K et al. Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649. ASCO Gastrointestinal Cancers Symposium 2022;Abstract 240.
Shitara K et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022;603(7903):942-8. Abstract
Sihag S et al. The role of the TP53 pathway in predicting response to neoadjuvant therapy in esophageal adenocarcinoma. Clin Cancer Res 2022;[Online ahead of print]. Abstract
Tabernero J et al. KEYNOTE-859: A Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. Future Oncol 2021;17(22):2847-55. Abstract